Therapy Optimization in Multiple Sclerosis (MS) 
      The purpose of this study is to determine if higher compliance and adherence rates to drug
      therapy for MS result in better health outcomes than lower rates of therapy compliance and
      adherence.
     Multiple Sclerosis :

          -  Male or female, 18 years of age or older, with a diagnosis of MS.

          -  Being treated with Glatiramer Acetate (GA) or (IFN)-β

          -  Receiving therapy from a participating Specialty Pharmacy

         :

          -  Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become
             pregnant, or breast feeding during the study

          -  Has received an experimental drug in the last thirty (30) days other than Fampridine
             SR (4-aminopyridine or 4-AP)

          -  Unlikely to be able to participate for the full two years of the study
      